
    
      Patients are randomized to one of three treatment regimens: ddC alone, Ro 31-8959 alone, and
      ddC plus Ro 31-8959. Treatment continues for at least 48 weeks. Patients are stratified by
      baseline CD4 count. (Per 09/26/94 amendment, a fourth arm, lower dose Ro 31-8959 plus ddC,
      was discontinued.)
    
  